No CrossRef data available.
Article contents
Clinical Experiences and Clinical Trials
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Communique
- Information
- Copyright
- Copyright © Cambridge University Press 2008
References
REFERENCES
1.Marder, SR. Newer antipsychotics and the difference between clinical experiences and clinical trials. CNS Spectr. 2007;12:812–815.Google ScholarPubMed
2.Lieberman, JA, Stroup, TS, McEvoy, JP, et al, for the CATIE Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Eng J Med. 2005;353:1209–1223.CrossRefGoogle Scholar
3.Rosenheck, RA, Leslie, D, Sindelar, J, et al.Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080–2089.Google Scholar
4.Keefe, RSE, Bilder, RM, Davis, SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effect of antipsychotic medications in patients with chronic schizophrenia in the CATIE study. Arch Gen Psychiatry. 2007;64:633–647.Google Scholar
5.Swartz, M, Perkins, D, Stroup, S, et al; CATIE Investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE Study. Am J Psychiatry. 2007;164:428–436.CrossRefGoogle ScholarPubMed
6.Resnick, SG, Rosenheck, RA, Stroup, TS, et al for the CATIE Study Investigators. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res. 2008; In press.Google Scholar
7.Swanson, JW, Swartz, MS, Van Dorn, RA, et al for the CATIE Investigators. Effectiveness of antipsychotic drugs for reducing violence in persons with chronic schizophrenia: Findings from the NIMH CATIE Study. Br J Psychiatry. 2008; In press.Google Scholar
8.Rosenheck, RA, Stroup, TS, Keefe, RSE, McEvoy, J, Swartz, M, Lieberman, JA. Study samples key to assessing risk [letter]. Current Psychiatry. 2007;6:3–4.Google Scholar
9.Tollefson, GD, Beasley, CM Jr, Tran, PV, et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457–465.Google Scholar
10.Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–835.Google Scholar
11.Hogan, TP, Awad, AG, Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.Google Scholar
12.Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.Google Scholar
13.Halliday, J, Farrington, S, Macdonald, S, MacEwan, T, Sharkey, V, McCreadie, R. Nithsdale Schizophrenia Surveys 23: movement disorders 20-year review. Br J Psychiatry. 2002;181:422–427.Google Scholar
14.Lee, PE, Sykora, K, Gill, SS, et al.Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374–1379.Google Scholar
15.Rochon, PA, Stukel, TA, Sykora, K, et al.Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882–1888.Google Scholar
16.Bausell, RB. Snake Oil Science: The Truth About Complementary and Alternative Medicine. New York, NY: Oxford University Press; 2007.Google Scholar
17.Ariely, D. The power of price: why a 50-cent aspirin can do what a penny aspirin can't. In: Predictably Irrational: The Hidden Forces That Shape Our Decisions. New York, NY: HarperCollins; 2008;173–194.Google Scholar
You have
Access